Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Brown, Jennifer R. [1 ]
Eichhorst, Barbara [2 ]
Ghia, Paolo [3 ,4 ]
Kater, A. P. [5 ]
Li, Jianyong [6 ]
Khurana, Sudha [7 ]
Elhamy, Mostafa [7 ]
Wang, Min Hui [7 ]
Seymour, John F. [8 ,9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Hosp Cologne, Cologne, Germany
[3] Univ Vita Salute Raffaele, Milan, Italy
[4] IRCCS Osped San Raffaele, Milan, Italy
[5] Amsterdam UMC, Amsterdam, Netherlands
[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China
[7] Acerta Pharma, San Francisco, CA USA
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-092
引用
收藏
页码：S221 / S222
页数：2
相关论文
共 50 条
  • [1] MAJIC: a phase III trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
    Ryan, Christine E.
    Davids, Matthew S.
    Hermann, Richard
    Shahkarami, Mina
    Biondo, Juliana
    Abhyankar, Sarang
    Alhasani, Hasan
    Sharman, Jeff P.
    Mato, Anthony R.
    Roeker, Lindsey E.
    FUTURE ONCOLOGY, 2022, 18 (33) : 3689 - 3699
  • [2] Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China
    Li, Mengya
    Zhong, Xiaoyan
    Zhang, Chengbin
    Luo, Hongli
    Luo, Li
    Huang, Yilan
    Jiang, Longyang
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [3] Phase 3 BELLWAVE-011 Study: Nemtabrutinib Versus Ibrutinib or Acalabrutinib in Previously Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Tadmor, Tamar
    Eyre, Toby A.
    Benjamini, Ohad
    Chaudhry, Arvind
    Shen, Juan
    Leng, Siyang
    Farooqui, Mohammed
    Lavie, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S352 - S353
  • [4] A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia
    Kay, Neil E.
    Strati, Paolo
    LaPlant, Betsy R.
    Leis, Jose F.
    Nikcevich, Daniel
    Call, Timothy G.
    Pettinger, Adam M.
    Lesnick, Connie E.
    Hanson, Curtis A.
    Shanafelt, Tait D.
    ONCOTARGET, 2016, 7 (48) : 78269 - 78280
  • [5] Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia
    Gay, Nathan D.
    Kozin, Eliana
    Okada, Craig
    Danilov, Alexey V.
    Spurgeon, Stephen
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2258 - 2260
  • [6] Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 5-Year Results of the Randomized CLL14 Study
    Al-Sawaf, Othman
    Zhang, Can
    Robrecht, Sandra
    Kotak, Alex
    Chang, Naomi
    Fink, Anna
    Tausch, Eugen
    Schneider, Christof
    Ritgen, Matthias
    Kreuzer, Karl
    Chyla, Brenda
    Eichhorst, Barbara
    Jiang, Yanwen
    Stilgenbauer, Stephan
    Hallek, Michael
    Fischer, Kirsten
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S274 - S275
  • [7] Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
    Flinn, Ian W.
    Gribben, John G.
    Dyer, Martin J. S.
    Wierda, William
    Maris, Michael B.
    Furman, Richard R.
    Hillmen, Peter
    Rogers, Kerry A.
    Iyer, Swaminathan Padmanabhan
    Quillet-Mary, Anne
    Ysebaert, Loic
    Walter, Harriet S.
    Verdugo, Maria
    Klein, Christian
    Huang, Huang
    Jiang, Yanwen
    Lozanski, Gerard
    Pignataro, Daniela Soriano
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kipps, Thomas J.
    BLOOD, 2019, 133 (26) : 2765 - 2775
  • [8] Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
    Hill, Brian T.
    Kalaycio, Matt
    ONCOTARGETS AND THERAPY, 2015, 8 : 2391 - 2397
  • [9] First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia
    Byrd, John C.
    Hillmen, Peter
    Ghia, Paolo
    Kater, Arnon P.
    Chanan-Khan, Asher
    Furman, Richard R.
    O'Brien, Susan
    Yenerel, Mustafa Nuri
    Illes, Arpad
    Kay, Neil
    Garcia-Marco, Jose A.
    Mato, Anthony
    Pinilla-Ibarz, Javier
    Seymour, John F.
    Lepretre, Stephane
    Stilgenbauer, Stephan
    Robak, Tadeusz
    Patel, Priti
    Higgins, Kara
    Sohoni, Sophia
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S318 - S318
  • [10] Ofatumumab-Based Chemoimmunotherapy Is Effective and Well Tolerated in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Shanafelt, Tait
    Lanasa, Mark C.
    Call, Timothy G.
    Beaven, Anne W.
    Leis, Jose F.
    LaPlant, Betsy
    Bowen, Deborah
    Conte, Michael
    Jelinek, Diane F.
    Hanson, Curtis A.
    Kay, Neil E.
    Zent, Clive S.
    CANCER, 2013, 119 (21) : 3788 - 3796
12345